we have had 3 other “ new drug” anncts over time. Only the kidney drug nearing the clinic made the SP move much. If you project from that this won’t move the share price until efficacy in humans is proven, as with RP11 drug which had a small effect only. The sum of the moving parts, and the platform make this a very serious sleeper. If you’ve got a reasonable time frame parking some cash here will almost certainly prove to outperform over 1-2yrs. ( not inv advice of course)
My hope in the near term is that the suppressed share price will lead PYC down the BD deal in the near future…..whenever that is.
Ann: PYC Nominates Fourth Clinical Drug Candidate in PMS Program, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.025(2.11%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.16 | $45.30K | 38.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4346 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 563 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |